Incyte has taken an ax to its suite of late-phase epacadostat trials after digesting the implications of last month’s pivotal study blowup. The cull sees Incyte downgrade two pivotal epacadostat-Keytruda trials to phase 2 studies and back away from six other late-stage tests of its IDO inhibitor.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,